FI906367A - Terapeutiska nukleosider. - Google Patents

Terapeutiska nukleosider. Download PDF

Info

Publication number
FI906367A
FI906367A FI906367A FI906367A FI906367A FI 906367 A FI906367 A FI 906367A FI 906367 A FI906367 A FI 906367A FI 906367 A FI906367 A FI 906367A FI 906367 A FI906367 A FI 906367A
Authority
FI
Finland
Prior art keywords
nucleosider
therapeutic
therapeutic nucleosider
Prior art date
Application number
FI906367A
Other languages
English (en)
Other versions
FI106461B (fi
FI906367A0 (fi
Inventor
Susan Mary Daluge
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/455,201 external-priority patent/US5034394A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI906367A0 publication Critical patent/FI906367A0/fi
Publication of FI906367A publication Critical patent/FI906367A/fi
Priority to FI970666A priority Critical patent/FI105813B/fi
Application granted granted Critical
Publication of FI106461B publication Critical patent/FI106461B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI906367A 1989-12-22 1990-12-21 Menetelmä terapeuttisesti käyttökelpoisten enantiomeeristen yhdisteiden valmistamiseksi sekä menetelmässä käyttökelpoinen välituote FI106461B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI970666A FI105813B (fi) 1989-12-22 1997-02-17 Enantiomeerisia välituotteita

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/455,201 US5034394A (en) 1988-06-27 1989-12-22 Therapeutic nucleosides
US45520189 1989-12-22

Publications (3)

Publication Number Publication Date
FI906367A0 FI906367A0 (fi) 1990-12-21
FI906367A true FI906367A (fi) 1991-06-23
FI106461B FI106461B (fi) 2001-02-15

Family

ID=23807819

Family Applications (2)

Application Number Title Priority Date Filing Date
FI906367A FI106461B (fi) 1989-12-22 1990-12-21 Menetelmä terapeuttisesti käyttökelpoisten enantiomeeristen yhdisteiden valmistamiseksi sekä menetelmässä käyttökelpoinen välituote
FI20001175A FI20001175A (fi) 1989-12-22 2000-05-16 Enantiomeerisia yhdisteitä, jotka ovat oleellisesti vapaita vastaenantiomeereista

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20001175A FI20001175A (fi) 1989-12-22 2000-05-16 Enantiomeerisia yhdisteitä, jotka ovat oleellisesti vapaita vastaenantiomeereista

Country Status (30)

Country Link
EP (3) EP0434450B1 (fi)
JP (2) JPH11158160A (fi)
CN (1) CN1028106C (fi)
AP (1) AP196A (fi)
AT (1) ATE181917T1 (fi)
AU (1) AU633672B2 (fi)
CA (1) CA2033044C (fi)
CY (1) CY2145B1 (fi)
CZ (1) CZ283481B6 (fi)
DE (2) DE19975058I1 (fi)
DK (1) DK0434450T3 (fi)
ES (1) ES2133138T3 (fi)
FI (2) FI106461B (fi)
GR (1) GR3031100T3 (fi)
HK (1) HK1009600A1 (fi)
HU (3) HU220067B (fi)
IE (3) IE990825A1 (fi)
IL (1) IL96748A (fi)
LU (1) LU90426I2 (fi)
MX (1) MX9203215A (fi)
MY (1) MY104575A (fi)
NL (1) NL990028I2 (fi)
NZ (1) NZ236593A (fi)
PL (1) PL167097B1 (fi)
PT (1) PT96321B (fi)
RU (2) RU2068849C1 (fi)
SG (1) SG49685A1 (fi)
SK (2) SK658390A3 (fi)
TW (2) TW473466B (fi)
ZA (1) ZA9010365B (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229531B (it) * 1988-01-20 1991-09-04 Univ Minnesota Composti nucleosidi dideossidideidrocarbociclici e formulazione farmaceutica che li contiene
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB9108376D0 (en) * 1991-04-19 1991-06-05 Enzymatix Ltd Cyclopentenes
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
EP0702556B1 (en) * 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
WO1996006620A2 (en) 1994-08-29 1996-03-07 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
ATE230267T1 (de) * 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
SK284810B6 (sk) * 1997-05-13 2005-12-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purín-9-yl)-2-cyklopentén-1-metanolu
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
JP2001522850A (ja) * 1997-11-12 2001-11-20 グラクソ グループ リミテッド キラルヌクレオシド類似体の製造法
CZ298144B6 (cs) * 1997-11-27 2007-07-04 Lonza Ag Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
KR100606625B1 (ko) 1998-10-30 2006-07-28 론자 아게 4-[(2',5'-디아미노-6'-할로피리미딘-4'-일)아미노]-시클로펜트-2-에닐메탄올의 제조 방법
ATE240945T1 (de) * 1998-10-30 2003-06-15 Lonza Ag Verfahren zur herstellung von 4-((2',5'-diamino- 6'-halogenpyrimidin-4'-yl)amino)-cyclopent-2- enylmethanolen
GB9903091D0 (en) 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
AU2576001A (en) * 1999-12-10 2001-06-18 Glaxo Group Limited (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
KR100891366B1 (ko) 2001-06-29 2009-04-02 인스티튜트 오브 오르가닉 케미스트리 앤드 바이오케미스트리, 어케더미 오브 사이언시스 오브 더 체크 리퍼블릭 항 바이러스 활성을 갖는 6-'2-(포스포노메톡시)알콕시 피리미딘 유도체
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003018745A2 (en) * 2001-08-21 2003-03-06 Glaxo Group Limited Method of screening for drug hypersensitivity reaction
US7550261B2 (en) 2001-08-21 2009-06-23 Smithkline Beecham Corporation Method of screening for drug hypersensitivity reaction
US7551837B2 (en) 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR20050013628A (ko) * 2002-06-27 2005-02-04 메디비르 아베 아바카비르와 알로부딘의 공동상승 상호작용
CN1805966B (zh) 2003-06-16 2013-03-13 捷克科学院有机化学和生物化学研究所 作为抗病毒核苷酸类似物的含膦酸酯基团的嘧啶化合物
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
AU2007301934A1 (en) * 2006-09-28 2008-04-03 Esteve Quimica, S.A. Process for the preparation of abacavir
EP1905772A1 (en) * 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
RU2443703C2 (ru) 2007-06-18 2012-02-27 Саншайн Лейк Фарма Ко., Лтд Бром-фенил замещенные тиазолилдигидропиримидины
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
EP2340252B1 (en) 2008-09-09 2015-11-11 AstraZeneca AB A process for preparing [1s- ]1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ]-3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino]- 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d]pyrimidin-3-yl]-5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
EP2800750B1 (en) * 2012-01-03 2016-11-23 Cellceutix Corporation Carbocyclic nucleosides and their pharmaceutical use and compositions
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer
ES2651854T3 (es) 2013-10-03 2018-01-30 Lupin Limited Clorhidrato de abacavir monohidrato cristalino y procedimiento para su preparación
CN104558035B (zh) * 2013-10-22 2017-12-19 连云港恒运药业有限公司 一种替诺福韦前药的纯化方法
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN109239253B (zh) * 2018-09-21 2021-07-09 江苏威奇达药业有限公司 一种阿巴卡韦的杂质的高效液相检测方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
IT1229531B (it) * 1988-01-20 1991-09-04 Univ Minnesota Composti nucleosidi dideossidideidrocarbociclici e formulazione farmaceutica che li contiene
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE68907013D1 (de) * 1988-10-24 1993-07-15 Wellcome Found Guaninderivate mit antiviraler wirkung und deren pharmazeutisch vertraegliche salze.
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US4939252A (en) * 1989-04-20 1990-07-03 Hoffmann-La Roche Inc. Novel intermediates for the preparation of Carbovir

Also Published As

Publication number Publication date
ZA9010365B (en) 1992-08-26
HU220630B1 (hu) 2002-03-28
LU90426I2 (fr) 1999-10-06
PL167097B1 (pl) 1995-07-31
HU9902543D0 (en) 1999-10-28
MY104575A (en) 1994-04-30
AU633672B2 (en) 1993-02-04
DK0434450T3 (da) 2000-01-31
GR3031100T3 (en) 1999-12-31
EP0434450B1 (en) 1999-07-07
DE19975058I1 (de) 2007-01-25
HK1009600A1 (en) 1999-06-04
TW473466B (en) 2002-01-21
FI20001175A (fi) 2000-05-16
HU219454B (hu) 2001-04-28
EP0921121A1 (en) 1999-06-09
DE69033197T2 (de) 1999-10-28
NL990028I1 (nl) 1999-11-01
CZ283481B6 (cs) 1998-04-15
SG49685A1 (en) 1998-06-15
IL96748A0 (en) 1991-09-16
ES2133138T3 (es) 1999-09-01
IE990826A1 (en) 2000-12-13
MX9203215A (es) 1992-07-01
SK247092A3 (en) 1999-06-11
AU6841990A (en) 1991-06-27
SK280216B6 (sk) 1999-10-08
AP9000234A0 (en) 1991-01-31
FI106461B (fi) 2001-02-15
CA2033044A1 (en) 1991-06-23
DE69033197D1 (de) 1999-08-12
IL96748A (en) 1995-07-31
NL990028I2 (nl) 2000-02-01
EP0434450A2 (en) 1991-06-26
CA2033044C (en) 1999-07-13
RU2068849C1 (ru) 1996-11-10
SK280000B6 (sk) 1999-06-11
CN1028106C (zh) 1995-04-05
PT96321A (pt) 1991-09-30
AP196A (en) 1992-06-30
HU9902539D0 (en) 1999-10-28
CN1054981A (zh) 1991-10-02
IE990825A1 (en) 2000-12-13
ATE181917T1 (de) 1999-07-15
HU220067B (hu) 2001-10-28
HU9008407D0 (en) 1991-07-29
JPH11343292A (ja) 1999-12-14
NZ236593A (en) 1994-01-26
CY2145B1 (en) 2002-06-21
IE904652A1 (en) 1991-07-17
RU2091386C1 (ru) 1997-09-27
SK658390A3 (en) 1999-10-08
JPH11158160A (ja) 1999-06-15
PT96321B (pt) 1998-06-30
EP0434450A3 (en) 1992-07-08
EP0921114A1 (en) 1999-06-09
CZ658390A3 (en) 1997-11-12
TW371660B (en) 1999-10-11
FI906367A0 (fi) 1990-12-21
PL288403A1 (en) 1992-06-26

Similar Documents

Publication Publication Date Title
FI906367A (fi) Terapeutiska nukleosider.
FI913899A0 (fi) Terapeutiska aerosolblandningar.
ATE120194T1 (de) Therapeutische nuleoside.
FI903656A0 (fi) Terapeutiska kinuklidinfoereningar.
FI883757A (fi) Terapeutiska nukleosider.
FI881651A (fi) Terapeutiska nukleosider.
DE59007974D1 (de) Uretero-Renoskop.
FI904854A0 (fi) Terapeutiska nukleosider.
FI902973A0 (fi) Magnetfaeltsgenerator foer terapeutiska aendamaol.
FI893897A0 (fi) Terapeutiska nukleosider.
NO902335L (no) Vaeskebeholdere.
FI923486A0 (fi) Terapeutiska aemnen.
FI881216A (fi) Terapeutiska nukleosider.
FI894321A0 (fi) Terapeutiska aemnen.
FI910753A0 (fi) Terapeutiska nukleocider.
DE69005107D1 (de) Fusskreuz.
FI923528A0 (fi) Terapeutiska aemnen.
FI912852A0 (fi) Terapeutiska dekapeptider.
DE59004564D1 (de) Mappe.
NO901573D0 (no) Terapeutiske midler.
NO901574D0 (no) Terapeutiske midler.
ES1008798Y (es) Bolsa-mochila.
ES1011811Y (es) Muneco-envase.
FI892374A0 (fi) Anordning foer foerflyttning av patient.
FI891231A0 (fi) Anordning foer foerflyttning av patient.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: THE WELLCOME FOUNDATION LIMITED

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L190

Extension date: 20140627